Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs
- Status
- Active not recruitingResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to 75 Years; excludes diabetes; BMI ≥25 required; conditions: Heart Failure; Diabete Type 2; Arterial Hypertension
- Interventions
- Tirzepatide (Mounjaro); dapagliflozin, empagliflozin, metformin
- Conditions
- Heart Failure; Diabete Type 2; Arterial Hypertension
- Phase and size
- NA · 120 participants
- Dates
- Start 2024-12-18
Primary completion 2025-07-01 - Sponsor
- Nazarbayev University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Change in NT-proBNP levels from baseline to Week 24Baseline to Week 24
02Eligibility
Who can take part
Inclusion Criteria: * Chronic heart failure with preserved ejection fraction (left ventricular ejection fraction not ≤ 45%) * Type 2 diabetes mellitus (T2DM) with HbA1c level between ≥7.0% and ≤10.5% * Ongoing treatment for T2DM (e.g., metformin and/or sulfonylureas, or basal insulin therapy) * Stable body weight (±5%) for at least 3 months prior to screening * Body mass index (BMI) ≥ 25 kg/m² * Possible inclusion of patients with chronic pancreatitis in remission * Aged 18 years or older, and not older than 75 years * Both male and female participants Exclusion Criteria: * Type 1 diabetes mellitus * Exacerbation of chronic pancreatitis * Acute pancreatitis * Proliferative diabetic retinopathy, diabetic maculopathy, or non-proliferative diabetic retinopathy * History of bariatric (weight-loss) surgery or conditions associated with delayed gastric emptying * Acute or chronic hepatitis * Chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) \< 45 ml/min/1.73 m² * Myocardial infarction or stroke within the past 2 months * Medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) in the participant or a first-degree relative * Use of any other antidiabetic medications (except metformin and/or sulfonylureas and basal insulin) within the past 3 months * Use of weight loss medications, including over-the-counter drugs, within the past 3 months * History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorders within the past 2 years * Healthy individuals (no cardiovascular or metabolic disease)
03Change log
Registry changes
No changes recorded since the trial was added.